In this episode of the SOHO Insider podcast, Andrew Kuykendall, MD, assistant member at Moffitt Cancer Center, and Douglas Tremblay, MD, assistant professor of medicine at Icahn School of Medicine at Mount Sinai, discuss how to approach the treatment of essential thrombocythemia.

“The first thing I do whenever a patient walks into the clinic with ET is think about their risk status,” Dr. Tremblay said. “When we speak about risk status, what we’re really speaking about is risk of thrombosis. There’s several different risk stratification methods, but they all rely on three clinical factors in general, which is age of prior thrombosis, which is probably the most potent risk factor.”

This episode also includes a discussion on the SURPASS-ET trial, which showed ropeginterferon alfa-2b outperformed anagrelide for disease control. Plus, a look into how new CALR-targeted antibodies improve bone marrow in early studies.

Dr. Masarova discusses SURPASS-ET study at EHA 2025

In this episode of the SOHO Insider podcast, Thomas Martin, MD, professor of medicine at University of California, San Francisco, talks with patient Craig Chase, an American father of two who was diagnosed with myeloma in 2014; Chase was the only American to travel to Nanjing, China, in 2017 to receive ciltacabtagene autoleucel (cilta-cel; then LCAR-B38M).

Chase shares his experience traveling to China for the therapy as a heavily-treated patient with limited treatment options. Chase talked about his treatment journey, his experience being treated in a foreign country with an experiment therapy, and what it was like achieving long-term remission.

Dr. Martin also discussed the five-year CARTITUDE-1 follow-up date presented at both ASCO(R) and EHA 2025. Those date showed that one-third of myeloma patients were in remission more than five years after cilta-cel treatment. The results of these trials and other trial data on therapies other than cilta-cel, prompted Sundar Jagannath, MD, during SOHO 2025 to address the potential of using the word cure when speaking with patients.

SOHO Insider lymphoma podcast host Megan Melody, MD, assistant professor at the University of South Florida, interviews Tara Graff, MD, director of clinical trials and lymphoma specialist at Mission Cancer and Blood, part of University of Iowa Health Care, on treating patients with blood cancers in community settings, and whether the future belongs to bispecific antibodies or CAR-T therapies.

“To be able to give your patients these novel therapies is amazing,” Dr. Graff said on the podcast. “I think it’s going to be a bispecific-versus-CAR-T world in all the different disease states of lymphoma. But I don’t think I would choose one or the other across the board.”

They also discussed how hematologist-oncologists can support colleagues who have not managed toxicities associated with cell therapies.

“I think we’re just going to have to be patient and really help, because if we don’t help them, all the specialists are going to wind up seeing all the other specialties’ patients,” Dr. Graff said. “And there’s no way we can do that. It’s just being patient and helping each other.”

Listen to more SOHO Insider podcasts.

Read more about Dr. Melody here.

Ahead of SOHO Breakthroughs in Blood Cancers—and in the spirit of end-of-year lists—SOHO Insider asked Dr. Vose for her take on the biggest lymphoma developments of 2025. Her answer: bispecific antibodies continue to dominate the field.

She noted that the biggest shift in the field is moving away from chemotherapy alone and toward immunotherapy and bispecific-based approaches.

Dr. Vose will be speaking at 12:30 pm Central time on November 20, 2025, during SBBC. At 12:55 pm Central time, attendees can ask questions via the virtual platform.

Dr. Vose points to a major shift toward integrating bispecifics in combination regimens with chemotherapy to help patients reach CAR-T or transplant, and now increasingly in frontline therapy for diffuse large B-cell lymphoma and follicular lymphoma.

She highlighted both the STARGLO study, a randomized, global, phase 3 study that is evaluating glofitamab plus gemcitabine and oxaliplatin in the relapsed or refractory setting in DLBCL, and the SUNMO phase 3 trial that is evaluating mosunetuzumab plus polatuzumab vedotin to R-GemOx in transplant-ineligible patients with relapsed or refractory LBCL.

There is still time to register at soho.click/SBBC. Registration is free for SOHO members and $50 for non-SOHO members. Join SOHO for free today.

In this SOHO Insider podcast, Saad Usmani, MD, chief of the myeloma service at Memorial Sloan Kettering Cancer Center, and Niels W C J van de Donk, MD, professor of hematology at Amsterdam UMC, provide an overview of immunotherapies. They discuss bispecific and trispecific antibodies, including early data from the trispecifics and the therapies moving into the frontline setting in multiple myeloma treatment.

The pair spoke about the novel trispecific antibody JNJ-5322 that targets BCMA and GPRC5D via T-cell redirection and ISB 2001, an investigational trispecific antibody that received FDA fast track designation earlier in 2025.

“The future looks bright for the trispecifics,” Dr. van de Donk said. “We are also looking at combination strategies now in that patients with earlier, lines of therapy, less prior lines of therapy, we are even testing the trispecific now in combination with dara in newly diagnosed patients and the future hopefully again challenging transplant which is still a key component in Europe for the newly diagnosed myeloma patient.

Listen to more SOHO Insider podcasts.

In this episode of the SOHO Insider podcast, Susan O’Brien, MD, a professor of medicine from the Chao Family Comprehensive Cancer Center at the University of California, Irvine Medical Center, and Nitin Jain, MD, professor of medicine in the Department of Leukemia at the University of Texas MD Anderson Cancer Center, discuss updated results from the phase 3 FLAIR trial; the pair also speak about Bruton’s tyrosine kinase degraders in treating CLL.

Sagar Lonial, MD, and Saad Usmani, MD, provide a sneak peek on what attendees can expect to learn at SOHO Breakthroughs in Blood Cancers (SBBC). Dr. Lonial will be the presenter of the myeloma session at the meeting. His talk is scheduled for 1:35 pm Central time on November 20, 2025.

SBBC is a new virtual meeting from SOHO and is chaired by Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center. SBBC takes place at 8 am—5 pm Central time on November 20, 2025. Register today at soho.click/SBBC. To view the entire program, visit the SBBC website.

SOHO members register for free; $50 for non-SOHO members. To become a SOHO member go to soho.click/join.

Saad Usmani, MD, chief of the myeloma service and Eytan Stein, MD, chief of the leukemia service, both from Memorial Sloan Kettering Cancer Center, discuss menin inhibitors and the future of leukemia research in this podcast episode of SOHO Insider.

Dr. Stein discusses the development of the first menin inhibitor approved the US Food and Drug Administration for relapsed or refractory acute leukemia with a KMTA translocation.

“The response rate is in the range of 60% to 70%,” noted Dr. Stein, including 30% complete remission or partial hematologic recovery.

“I think the big issue with menin inhibitors is that they’re not durable,” Dr. Stein said. “Patients go into remission… for something like six to nine months, but then they eventually relapse.”

About combination therapies, Dr. Stein said the goal was to follow the myeloma treatment paradigm.

“I think that what you all have done in myeloma is what we’re looking to do in leukemia,”he said, adding that the combination therapies will “hopefully lead to more durable remissions and allow more people to have successful … transplants, which seems to be still the best anti-leukemia therapy in 2025.”

Ten years from now, Dr. Stein said he would like to see more intensive therapy upfront.

“10 years from now, what I’m hoping is that transplant is reserved for patients with the highest-risk disease,” he said. “[And] that we’re able to give intensive therapy upfront and then move to a maintenance strategy, where you’re giving targeted agents as your maintenance approach with those targeted agents having many fewer side effects.”

Listen to more episodes.